commercial pharma deals

When you research the deals that were done recently with other Biotech companies (as in the last year)& mentioned on Page 7 of latest shareholders letter, even before Phase 11(a or b) trials were finished, you clearly get the idea that NN is doing a job on us & probably hopes we stay this naive until they can get their hands on X-Toll.

I think we've been dumbed down when you look at the huge results of these 2 deals reported on these weblinks:

http://www.contractpharma.com/contents/view_breaking-news/2011-06-20/alder-hits-15-million-bms-milestone/

http://www.nature.com/nrd/journal/v9/n1/full/nrd3094.html

http://www.thepharmaletter.com/file/58565/lilly-gains-global-rights-to-incytes-novel-jak1jak2-inhibitor-for-90-million-upfront-and-up-to-665-million-more-deal-with-pdl.html

http://newsroom.lilly.com/releasedetail.cfm?releaseid=431576

http://www.fiercebiotech.com/story/alder-lands-15m-milestone-blockbuster-bms-antibody-deal/2011-06-20